Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-30
SponsorMayo Clinic
About this trial
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
Eligibility criteria
Qualifiers
ADPKD (based on Ravine et al. criteria)
Class 1 B-E according to our imaging classification
Male and female subjects 18 - 30 years of age, inclusive
Estimated GFR> 60 mL/min/m2 (CKD-EPI equation)
Disqualifiers
Class 2 according to our imaging classification
Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)
Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics).
Predicted urine protein excretion in urinalysis >1 g/24 hrs
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 2 trial groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov